Journal article

Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies

Abstract:: BACKGROUND: Bleeding among populations undergoing percutaneous coronary intervention or coronary artery bypass grafting and among conservatively managed patients with acute coronary syndrome exposed to different dual antiplatelet therapy and triple therapy (i.e. dual antiplatelet therapy plus an anticoagulant) has not been previously quantified.OBJECTIVES: The objectives were to estimate hazard ratios for bleeding for different antiplatelet and triple therapy regimens, estimate resources and ...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Harris, J., Pouwels, K. B., Johnson, T., Sterne, J., Pithara, C., Mahadevan, K., Reeves, B., Benedetto, U., Loke, Y., Lasserson, D., Doble, B., Hopewell-Kelly, N., Redwood, S., Wordsworth, S., Mumford, A., Rogers, C., & Pufulete, M. (2023). Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. Health Technology Assessment, 27(8), 1–257.

MLA Style

Harris, J, et al. “Bleeding Risk in Patients Prescribed Dual Antiplatelet Therapy and Triple Therapy after Coronary Interventions: the ADAPTT Retrospective Population-Based Cohort Studies.” Health Technology Assessment, vol. 27, no. 8, 2023, pp. 1–257.

Chicago Style

Harris, J, KB Pouwels, T Johnson, et al. 2023. “Bleeding Risk in Patients Prescribed Dual Antiplatelet Therapy and Triple Therapy after Coronary Interventions: the ADAPTT Retrospective Population-Based Cohort Studies.” Health Technology Assessment 27 (8): 1–257.
Print

Access Document

Files:: Harris_et_al_2023_Bleeding_risk_in.pdf

(Preview, Version of record, pdf, 5.6MB, Terms of use)

Publisher copy:: 10.3310/mnjy9014

Authors

+ Harris, J More by this author

Role:: Author
ORCID:: 0000-0002-4605-7710

+ Pouwels, KB More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Role:: Author

+ Johnson, T More by this author

Role:: Author
ORCID:: 0000-0003-4638-601X

+ Sterne, J More by this author

Role:: Author
ORCID:: 0000-0001-8496-6053

+ Pithara, C More by this author

Role:: Author
ORCID:: 0000-0003-2958-5201

More authors...

+ National Institute for Health and Care Research (NIHR) Health Technology Assessment programme More from this funder

Funder identifier:: 10.13039/501100000664
Grant:: 14/192/89

Publisher:: NIHR Journals Library
Journal:: Health Technology Assessment More from this journal
Volume:: 27
Issue:: 8
Pages:: 1-257
Publication date:: 2023-05-01
DOI:: 10.3310/mnjy9014
EISSN:: 2046-4924
ISSN:: 1366-5278

Language:: English
Keywords:: Population

Hazard ratio

Ticagrelor

Clopidogrel

Myocardial infarction

Medicine

Acute coronary syndrome

Surgery

Internal medicine

Cardiology

Percutaneous coronary intervention

Prasugrel

Aspirin

Confidence interval
Pubs id:: 1493553
Local pid:: pubs:1493553
Source identifiers:: W4383998246
Deposit date:: 2026-05-11
ARK identifier:: ark:/29072/ora_664fce087e684dcba6aa0c2215d597c0

Terms of use

Copyright date:: 2023

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP